What Is Compounded Tirzepatide? Understanding the Basics
Tirzepatide is the active pharmaceutical ingredient (API) in the brand-name medications Mounjaro® and Zepbound®, developed by Eli Lilly. As a dual GLP-1/GIP receptor agonist, it works by simultaneously activating two incretin hormone receptors — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This dual mechanism sets it apart from earlier GLP-1 medications and has produced remarkable results in clinical trials for both type 2 diabetes management and weight reduction.
The surge in demand for tirzepatide, combined with periods of supply shortage, led to the rise of compounded tirzepatide — versions of the drug prepared by compounding pharmacies rather than manufactured by Eli Lilly. Compounding is the practice of creating a customized medication for an individual patient, typically when a commercially available product cannot meet a specific clinical need.
For researchers and individuals following the peptide science space, understanding the distinction between FDA-approved tirzepatide and its compounded counterparts is essential — particularly given the sweeping regulatory changes that took effect in 2025 and 2026.
The Regulatory Landscape: What Changed in 2025–2026
The widespread availability of compounded tirzepatide was legally tied to its placement on the FDA's official drug shortage list. Under federal law, compounding pharmacies are permitted to prepare copies of FDA-approved drugs during a declared shortage. That window has now closed.
In October 2024, the FDA officially declared the tirzepatide shortage resolved. This determination was upheld in court in March 2025, removing the primary legal basis for mass compounding of tirzepatide. Two key enforcement deadlines followed:
- February 18, 2025: End of enforcement discretion for 503A state-licensed compounding pharmacies.
- March 19, 2025: End of enforcement discretion for 503B outsourcing facilities.
As of 2026, large-scale production and sale of compounded tirzepatide as a routine cost-saving alternative to brand-name products is no longer legally permitted in the United States. The FDA has also proposed permanently excluding tirzepatide from the list of bulk substances that 503B facilities can compound, regardless of future shortages.
Any pharmacy or online supplier currently marketing compounded tirzepatide for general use should be approached with significant caution. Researchers and consumers alike should be aware of this regulatory context before engaging with any compounded product.
503A vs. 503B Pharmacies: Key Distinctions
Understanding the two categories of compounding pharmacies is critical for evaluating any compounded peptide product.
503B Outsourcing Facilities
503B facilities are federally registered and inspected by the FDA. They are permitted to produce large, sterile batches of medications without individual patient prescriptions, often supplying hospitals and clinics. These facilities must adhere to Current Good Manufacturing Practice (cGMP) standards.
Current status: As of March 19, 2025, 503B facilities are fully prohibited from compounding tirzepatide. The FDA's proposal to formally exclude tirzepatide from the 503B Bulks List would make this prohibition permanent.
503A Compounding Pharmacies
503A pharmacies are state-licensed and may only compound medications for individual patients based on a valid, patient-specific prescription. Their oversight comes primarily from state boards of pharmacy.
Current status: A very narrow exception still exists for 503A pharmacies. To be legal, compounding must be based on a documented clinical justification from a licensed prescriber — such as a verifiable allergy to an inactive ingredient in the commercial product, or a specific clinical need that cannot be met by available commercial dose strengths. Cost savings alone do not qualify as a valid medical necessity.
The Salt Form Problem: A Critical Safety Concern
One of the most significant — and least understood — risks associated with compounded tirzepatide involves the chemical form of the active ingredient used in preparation.
Eli Lilly's Mounjaro® and Zepbound® use tirzepatide base — the specific molecular form that underwent rigorous clinical trials and received FDA approval. Some compounding pharmacies, however, have been found to use unapproved salt forms such as tirzepatide sodium or tirzepatide acetate.
The FDA explicitly considers these salt forms to be different active ingredients from the tirzepatide base. This distinction carries serious implications:
- Not bioequivalent: The FDA has not approved these salt forms and does not consider them bioequivalent to the base form. There is no scientific data confirming they are absorbed, distributed, and metabolized in the same way.
- Unknown safety profile: Salt forms have not been tested in large-scale, controlled human clinical trials. Their long-term effects and side-effect profile remain unknown.
- Dosage inaccuracy: A dose prepared with a salt form contains both the peptide and the salt molecule. If a pharmacy measures by weight, a labeled "10 mg dose" of tirzepatide acetate will contain less than 10 mg of the active tirzepatide peptide — leading to systematic underdosing.
When evaluating any compounded tirzepatide product for research purposes, confirming the use of tirzepatide base (not a salt form) is a non-negotiable quality checkpoint.
Reading a Certificate of Analysis (COA): What to Look For
For researchers working with any compounded peptide, the Certificate of Analysis (COA) is the primary quality verification document. A COA is issued by an independent third-party laboratory and confirms that a product meets its stated specifications.
A legitimate COA for compounded tirzepatide should verify the following:
- Identity: Confirms the active ingredient is tirzepatide — and specifically that the base form was used, not a salt form.
- Purity: Shows the percentage of active ingredient and lists any detected impurities.
- Potency/Concentration: Confirms the amount of active drug per mL (e.g., 10 mg/mL or 20 mg/mL), which is essential for accurate dosing calculations.
- Sterility: Certifies the product is free from bacterial or fungal contamination.
- Endotoxin levels: Ensures harmful bacterial byproducts are below safe thresholds.
Red flags that suggest a product may not be legitimate include: refusal to provide a COA, COAs from in-house labs rather than independent third parties, marketing of tirzepatide with additives like vitamin B12 as a "legal workaround," or claims of an oral tirzepatide formulation (no FDA-approved oral version exists).
Suppliers like Progressing (cpwt.shop) provide transparent documentation for their research peptide catalog, making it easier for researchers to verify product quality before use.
Dosing Considerations in Research Contexts
One of the most practically challenging aspects of working with compounded tirzepatide is dosing accuracy. FDA-approved Mounjaro® and Zepbound® are supplied in pre-filled, factory-calibrated single-use pens. Compounded versions, by contrast, are typically supplied in multi-dose vials requiring manual measurement with an insulin syringe.
Understanding Concentration and Volume
Compounding pharmacies prepare tirzepatide in a range of concentrations — commonly 5 mg/mL, 10 mg/mL, or 20 mg/mL. The concentration of the specific vial determines the volume that must be drawn for any given dose. Failing to account for concentration is the most common and potentially dangerous dosing error.
For example, a 5 mg research dose requires:
- From a 10 mg/mL vial: 50 units (0.5 mL)
- From a 20 mg/mL vial: 25 units (0.25 mL)
Drawing 50 units from a 20 mg/mL vial would deliver a 10 mg dose — double the intended amount. This type of error has been documented in adverse event reports submitted to the FDA.
Titration Protocols in Research
Clinical trial data for tirzepatide used a gradual titration approach, starting at lower doses and increasing over time to improve tolerability. Research protocols typically follow a similar stepwise approach, beginning at 2.5 mg and titrating upward in 2.5 mg increments every four weeks, based on individual response and tolerability. Consulting with a qualified healthcare professional before initiating any tirzepatide research protocol is strongly recommended.
Storage and Reconstitution: Handling Lyophilized Tirzepatide
Compounded tirzepatide is often supplied as a lyophilized (freeze-dried) powder that must be reconstituted with a sterile diluent before use. Proper handling is critical to maintain stability and sterility.
Storage Guidelines
- Unreconstituted powder: Store at controlled room temperature (18–25°C / 64–77°F). Do not refrigerate before reconstitution.
- Reconstituted solution: Store in a refrigerator at 2–8°C (36–46°F). Protect from light.
- Never freeze: Freezing destroys the peptide's protein structure, rendering it ineffective and potentially harmful.
- Stability window: When reconstituted with bacteriostatic water (which contains a preservative), the solution is typically stable for 21–28 days. If reconstituted with plain sterile water, use within 24 hours.
Reconstitution Protocol
- Gather supplies: tirzepatide vial, bacteriostatic water, alcohol swabs, and a mixing syringe. Wash hands thoroughly.
- Wipe the rubber stoppers of both vials with fresh alcohol swabs and allow to air dry.
- Draw the prescribed volume of bacteriostatic water into the syringe.
- Slowly inject the water into the tirzepatide vial, directing the stream against the inside wall to prevent foaming.
- Do not shake. Gently swirl or roll the vial between your palms until the powder is fully dissolved.
- Inspect the solution: it should be clear, colorless, and free of particles. Discard if cloudy, discolored, or particulate matter is visible.
Side Effects and Risk Profile
The side effect profile of tirzepatide has been extensively documented through large-scale clinical trials. Most adverse effects are gastrointestinal in nature, dose-dependent, and tend to diminish over time as the body adjusts.
Commonly Reported Side Effects
- Very common (>10%): Nausea, diarrhea, decreased appetite, vomiting
- Common (1–10%): Constipation, indigestion, abdominal discomfort, injection site reactions
Serious Risks
Tirzepatide carries an FDA boxed warning regarding thyroid C-cell tumors observed in animal studies. It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other serious but rare risks include pancreatitis, acute gallbladder disease, hypoglycemia (particularly when combined with other glucose-lowering agents), and potential kidney injury related to dehydration from gastrointestinal side effects.
Additional Risks Specific to Compounded Products
Beyond the known risks of the API itself, compounded tirzepatide introduces additional safety concerns that are not present with FDA-approved products:
- Contamination: FDA testing has found samples of compounded tirzepatide containing bacteria, elevated endotoxin levels, and other contaminants.
- Unknown impurities: Testing has revealed unidentified impurities in some compounded products. Notably, mixing tirzepatide with vitamin B12 — a practice used by some compounders — creates a new chemical impurity with unknown health effects.
- Potency inconsistencies: Some tested samples contained less active ingredient than labeled; others contained no tirzepatide at all.
- Mislabeling errors: The FDA has received reports of vials of insulin being mislabeled as tirzepatide — a potentially life-threatening error.
By April 2025, the FDA had received over 480 adverse event reports related to compounded tirzepatide. These figures underscore the importance of rigorous quality verification for any compounded peptide product used in research.
Comparing Compounded vs. FDA-Approved Tirzepatide
For researchers and clinicians evaluating the two options, the differences extend well beyond price:
- Manufacturing standards: FDA-approved products are manufactured under cGMP with rigorous quality controls. Compounded products are not subject to the same pre-market review.
- Bioequivalence data: The tirzepatide base in Mounjaro®/Zepbound® has been validated through extensive human trials. Compounded versions using salt forms lack this validation.
- Delivery system: Pre-filled pens eliminate measurement error. Multi-dose vials require precise manual calculation.
- Regulatory oversight: FDA-approved products are subject to post-market surveillance and recall mechanisms. Compounded products have limited oversight.
- Legal status: As of 2026, compounded tirzepatide for routine use is not legally permitted in the United States.
Key Takeaways for Researchers
The landscape for compounded tirzepatide has changed fundamentally. For those engaged in peptide research or following developments in GLP-1 science, several principles are worth keeping in mind:
- Always verify that any compounded peptide product comes with a third-party COA confirming identity, purity, potency, sterility, and endotoxin levels.
- Confirm that the tirzepatide base form — not a salt form — was used in preparation.
- Understand the concentration of any vial before calculating doses to avoid potentially dangerous measurement errors.
- Follow proper reconstitution and storage protocols to preserve peptide integrity.
- Consult a qualified healthcare professional before initiating any research protocol involving tirzepatide or related peptides.
The rapid evolution of GLP-1 science continues to generate important research questions. Staying informed about both the science and the regulatory environment is essential for anyone working in this space.